Latest news
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Iconovo has entered into a feasibility…
Iconovo Accelerator Program
On June 1st, 2023 Iconovo launched its Iconovo Accelerator to facilitate the opportunities for the company’s customers to obtain EU funding for the development…
Press releases
Nov 20, 2024, 09:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Nov 20, 2024, 09:00
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Nov 18, 2024, 19:35
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Nov 18, 2024, 19:35
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-top-disclaimer
Oct 30, 2024, 15:57
News
IR
English
Regulatory
MAR
Corporate Action
Other
Oct 30, 2024, 15:57
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Oct 30, 2024, 14:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Action
Prospectus
mfn-cus-top-disclaimer
Oct 30, 2024, 14:00
News
IR
English
Regulatory
Listing Regulation
Corporate Action
Prospectus
mfn-cus-top-disclaimer
Oct 29, 2024, 11:00
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Raport bolagsstämman
Sep 25, 2024, 18:05
News
IR
Swedish
Regulatory
Listing Regulation
Corporate Information
General meeting
Notice
Sep 25, 2024, 17:55
News
IR
English
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Sep 25, 2024, 17:55
News
IR
Swedish
Regulatory
MAR
Corporate Action
Shares
Issuance
mfn-cus-disclaimer
mfn-cus-top-disclaimer
Sep 20, 2024, 09:55
News
IR
Swedish
Corporate Action
Other
Sep 20, 2024, 09:55
News
IR
English
Corporate Action
Other
Sep 13, 2024, 12:41
News
IR
Swedish
Regulatory
MAR
Corporate Action
Other
Sep 13, 2024, 12:41
News
IR
English
Regulatory
MAR
Corporate Action
Other
Sep 10, 2024, 12:45
News
IR
Swedish
Correction
Regulatory
MAR
Corporate Action
Other
Sep 10, 2024, 12:45
News
IR
English
Correction
Regulatory
MAR
Corporate Action
Other
Possessing a unique combination
of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.
ICONOVO AB
VISITING ADDRESS
Ideon, Delta 6 Lund
Ideongatan 3B
POSTAL ADDRESS
Iconovo AB
Ideongatan 3A-B
SE-223 62 LUND
Sweden
CONTACT
Phone: +46 46 275 67 77
Director Business Development and Alliances
Måns Österberg
Mail: mans.osterberg@iconovo.se
Interim CEO
Anders Månsson
Mail: anders.mansson@iconovo.se